Abstracts tagged "prognostic factors"

Abstract Number: 0628 • ACR Convergence 2025
Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus
Panagiotis Garantziotis¹, Dionysis Nikolopoulos², Spyridon Katechis³, Alp Temiz⁴, Danae-Mona Nöthling¹, Christina Adamichou⁵, Prodromos Sidiropoulos⁶, Georg Schett⁷, Fanouriakis Antonis³, Dimitrios Boumpas⁸ and George Bertsias⁹, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ³National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical School University of Crete, Heraklion, Greece, Heraklion, Germany, ⁶Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ⁹Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece
Background/Purpose: Organ damage drives morbidity and mortality in systemic lupus erythematosus (SLE), yet no validated tools exist to predict early damage. We aimed to develop…
Abstract Number: 1811 • ACR Convergence 2025
Pharmacogenomic analysis of prediction of IL-1 Inhibitor treatment response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
Mariana Correia Marques¹, Michael Matt², Sophia Chou³, Peter Burbelo⁴, Zuoming Deng⁵, George Tomlinson⁶, Yukiko Kimura⁷, Grant Schulert² and Michael Ombrello⁸, ¹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Rockville, MD, ⁴Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, ⁵Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶University of Toronto, Toronto, ON, Canada, ⁷Hackensack Meridian School of Medicine, New York, NY, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Interleukin (IL)-1 inhibitors are now regarded as the first line treatment option for systemic juvenile idiopathic arthritis (sJIA), however in up to half of…
Abstract Number: 0620 • ACR Convergence 2025
The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
Luis Daniel Fajardo Hermosillo and María Karina Lizbeth López Ramírez, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, GUADALAJARA, Jalisco, Mexico
Background/Purpose: Remission in Systemic Lupus Erythematosus (SLE) is described by the Definition of Remission in SLE (DORIS), but it is hardly achieved in clinical practice,…
Abstract Number: 1648 • ACR Convergence 2025
Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)
Susan J. Bartlett¹, Marie-France Valois², Clifton Bingham³, Janet Pope⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Gilles Boire⁷, Carol Hitchon⁸, Glen Hazlewood⁹, Bindee Kuriya¹⁰, Carter Thorne¹¹ and Vivian Bykerk¹², ¹McGill University, Beaconsfield, QC, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³Johns Hopkins University, Baltimore, MD, ⁴University of Western Ontario, London, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷Retired, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Toronto - Toronto, Toronto, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Hospital for Special Surgery, New York, NY
Background/Purpose: Pain, fatigue, and emotional distress are common in new RA patients. It is unclear whether co-occurring symptoms predict worse outcomes and progression to advanced therapies…
Abstract Number: 0603 • ACR Convergence 2025
Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data
Amir Daneshvar¹, Areeb Tiwana², Dana Nachawati¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker³, Meghan Gump¹ and Omer Pamuk⁴, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²Canton Medical Education Foundation, Canton, OH, ³University hospitals Cleveland medical center, Highland Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with widespread clinical manifestations. Neuropsychiatric SLE (NPSLE), a complex and poorly understood subset of SLE,…
Abstract Number: 1579 • ACR Convergence 2025
Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease
Maria Iacovantuono¹, Nicholas landini², lisa Jungblut³, Florian Käs⁴, Rucsandra Dobrota⁵, Sinziana Muraru⁶, Carina Mihai⁷, Muriel Elhai⁸, Mike Becker⁹, Maria Sole Chimenti¹⁰, Thomas Frauenfelder³, Anna-Maria Hoffmann-Vold¹¹, Oliver Distler¹² and Cosimo Bruni¹³, ¹Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Spinete, Italy, ²Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ³Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁶University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁷University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, ⁹Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, Roma, Italy, ¹¹Oslo University Hospital, Oslo, Norway, ¹²Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc). Among radiomics features, the automated quantification of pulmonary vascular volume…
Abstract Number: 0598 • ACR Convergence 2025
Study of Long Term HCQ Safety on Cardiac Muscle Function in Patients with SLE and other Rheumatic Diseases
Jaspreet Bhatti¹, Kyu-In Lee², Nirali Sanghavi³, Stephen Zak⁴, Julia Ash⁵, James Miceli⁶, Kirk Sperber⁴, Stephen Pan⁷ and Amy Wasserman⁸, ¹Westchester Medical Center, Hopewell Junction, NY, ²Westchester Medical Center, Fort Lee, NJ, ³Westchester Medical Center, White Plains, NY, ⁴New York Medical College, Valhalla, ⁵Westchester Medical center, Dobbs Ferry, NY, ⁶Westchester Medical Center, Hawthorne, NY, ⁷Westchester Medical Center, Valhalla, ⁸New York Medical College at Westchester Medical Center, Armonk, NY
Background/Purpose: HCQ induced cardiomyopathy leading to heart failure is a rare but serious potential treatment complication. Currently there are no screening guidelines for detecting HCQ…
Abstract Number: 1562 • ACR Convergence 2025
Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study
adela cristina sarbu¹, Liubov Petelytska², lorenzo tofani³, Gianluca Moroncini⁴, Alexandra Balbir-Gurman⁵, elisabetta zanatta⁶, Jörg Henes⁷, paolo airò⁸, Marco Matucci-Cerinic⁹, Ana Maria Gheorghiu¹⁰, antonella marcoccia¹¹, branimir Anić¹², Jelena Colic¹³, Daniel Furst¹⁴, julia Spierings¹⁵, Francesco Del Galdo¹⁶, Britta Maurer¹⁷, Anna-Maria Hoffmann-Vold¹⁸, Oliver Distler¹⁹ and Cosimo Bruni²⁰, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Department of Rheumatology and Immunology, Bern University Hospital, University of Bern, Bern, Switzerland, bern, Swaziland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Dept Internal Medicine #³, Bogomolets National Medical University, Kyiv, Ukraine, Kyiv, Ukraine, ³Department of Statistics, Informatics and Applications, University of Florence, Florence, Italy, firenze, Italy, ⁴Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁵• Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Tecchnion, Haifa, Israel, Haifa, Israel, ⁶Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, ⁷Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁸Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, ⁹University San Raffaele Milano, Milano, Milan, Italy, ¹⁰Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ¹¹Centro di Riferimento Interdisciplinare per la Sclerosi Sistemica (CRIIS), Roma, Italy, rome, Italy, ¹²Department of Internal Medicine, Division of Clinical Immunology and Rheumatology, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Croatia, zagreb, Croatia, ¹³Institute of Rheumatology Belgrade, Belgrade, Serbia, Belgrade, Serbia, ¹⁴Southern California Scleroderma and Rheumatology Center, Los Angeles, CA, ¹⁵Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, ¹⁶University of Leeds, Leeds, United Kingdom, ¹⁷Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ¹⁸Oslo University Hospital, Oslo, Norway, ¹⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ²⁰University of Zurich, Zurich, Switzerland
Background/Purpose: Although most vasoactive vasodilating drugs (VVDs) exert anti-fibrotic effects in pre-clinical studies, randomized controlled trials assessing their efficacy in systemic sclerosis-associated interstitial lung disease…
Abstract Number: 0576 • ACR Convergence 2025
Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
Laura Coates¹, Philip J. Mease², Joseph Merola³, Lourdes Perez Chada⁴, Dafna D. Gladman⁵, Alen Zabotti⁶, Ulrich Mrowietz⁷, mitsumasa kishimoto⁸, Cynthia Deignan⁹, Siddharth Chaudhari¹⁰, Lichen Teng¹¹ and Laure Gossec¹², ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Harvard Medical School, Wayland, MA, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ⁷Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ⁸Kyorin University School of Medicine, Tokyo, Japan, ⁹Amgen, Inc., Agoura Hills, CA, ¹⁰Amgen Inc., Thousand Oaks, CA, ¹¹Amgen Inc., Thousand Oaks, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: FOREMOST (NCT03747939)1 offers novel insights on early oligoarticular (oligo, ≤4 active joints) PsA. Our aim was to analyse progression to polyarticular (poly; >4 active…
Abstract Number: 0814 • ACR Convergence 2024
Rare Variants of PAH Risk Genes Associate with a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension
Junyan Qian¹, Xinzhuang Yang², Yu Fang Ding³, qian wang¹, Jiuliang Zhao¹, Weida Liu⁴, Yongtai Liu⁵, Zhuang Tian⁵, Yanhong Wang⁶, Xiaojian Wang⁷, Mengtao Li¹ and Xiaofeng Zeng⁸, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ²Center for Bioinformatics, National Infrastructures for Translational Medicine, Institute of Clinical Medicine & Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, BEIJING, China (People's Republic), ⁴State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ⁶Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁷State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension (PAH) displays significant clinical heterogeneity; nevertheless, the underlying mechanisms remain unclear. Presently, more than twenty risk genes…
Abstract Number: 2247 • ACR Convergence 2024
Pro-inflammatory Monocytes and CD11c Expression in ACPA Positive Individuals with Arthralgia and Their Associations with Subclinical Synovitis Preceding the Onset of Arthritis
Klára Prajzlerová¹, Olga Kryštufková², Petra Hánová¹, Nora Růžičková², Hana Hulejová¹, Jiří Vencovský², Ladislav Šenolt² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Autoantibodies, e.g., against citrullinated proteins (ACPA), increase the risk of clinical arthritis and can be detected years before rheumatoid arthritis (RA) onset. EULAR's definition…
Abstract Number: 2665 • ACR Convergence 2024
Autoantibody Titers Against Specific Epitope Peptides Predict Treatment Resistance in Interstitial Lung Disease Associated with Anti-MDA5 Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima¹, Atsubumi Ogawa², Motohiro Nonaka², Norimichi Nomura², Yasuhiro Nohda², Mirei Shirakashi³, Ryosuke Hiwa², Hideaki Tsuji¹, Shuji Akizuki⁴, Hajime Yoshifuji¹, Tsuneyo Mimori⁵ and Akio Morinobu⁶, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Kyoto University, Kyoto, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁵Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is frequently associated with rapidly progressive interstitial lung disease (RP-ILD), leading to poor prognosis. Initial combinational therapy…
Abstract Number: 0037 • ACR Convergence 2024
Clonal Haematopoiesis of Indeterminate Potential (CHIP) Is Associated with Disease Activity in Rheumatoid Arthritis
Athena Chin¹, Sue Branford², Annabelle Small³, katie Lowe³, malcolm Smith⁴, Monika Kutyna⁵, Robert King², Susanna Proudman⁶, Devendra Hiwase⁷ and Mihir Wechalekar⁸, ¹Royal Adelaide Hospital, Tranmere, South Australia, Australia, ²SA Pathology, Adelaide, Australia, ³Flinders University, Adelaide, Australia, ⁴Flinders Medical Centre, Adelaide, Australia, ⁵South Australian Health and Medical Research Institute, Adelaide, Australia, ⁶Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Flinders Medical Centre, Bedford Park, Australia
Background/Purpose: Clonal haematopoiesis (CH) of indeterminate potential (CHIP) is defined as the detection of recurrent somatic mutations in genes that are known to drive haematological…
Abstract Number: 1133 • ACR Convergence 2024
Relationship Between Nail Psoriasis Severity Index (NAPSI) and Cardiovascular Risk Assessed by Eight Cardiovascular Risk Calculators
Maria F. Elizondo-Benitez¹, Iris Jazmín Colunga Pedraza², jose Ramon Azpiri-Lopez³, Dionicio Galarza-Delgado⁴, Jesus Cardenas-de la Garza⁵, Rosa Icela Arvizu-Rivera², Andrea Guajardo Aldaco² and Valeria Gonzalez-Gonzalez⁶, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory, and immune-mediated disease that affects up to 30% of psoriasis (PsO) patients. Nail psoriasis affects 80% of…
Abstract Number: 2286 • ACR Convergence 2024
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Josef Smolen¹, Gerd Burmester², Yoshiya Tanaka³, Tsutomu Takeuchi⁴, Jeffrey Curtis⁵, Ted Mikuls⁶, Clementina López Medina⁷, Peter C. Taylor⁸, Nicola Tilt⁹, Bernard Lauwerys¹⁰, Baran Ufuktepe¹¹ and Thomas Huizinga¹², ¹Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Reina Sofia University Hospital, Cordoba, Spain, ⁸University of Oxford, Oxford, United Kingdom, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Istanbul, Turkey, ¹²Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), including those treated with disease-modifying antirheumatic drugs, high rheumatoid factor (RF) levels are a poor prognostic factor,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].